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Background: Drug-drug interaction (DDI) is one of the main contributors to adverse drug
reactions and therefore, it is important to study its frequency in the population. We aimed
to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9
(CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data
from the pharmacy database IADB.nl.
Methods: As part of the University of Groningen PharmLines Initiative, data were
collected on CYP2D6/2C19/2C9-related substrate/inhibitors from entry questionnaires
of Lifelines participants and linked information from the pharmacy database IADB.nl.
CYP2D6/2C19/2C9 related co-prescriptions were divided based on the type of drugs i.e.
chronically used medication (CM) or occasionally used medication (OM). This resulted in
the combination of two chronically used drugs (CM-CM), chronically and occasionally
used medication (CM-OM), and two occasionally used drugs (OM-OM). To measure the
agreement level, cohen’s kappa statistics and test characteristics were used. Results
were stratified by time window, gender, and age.
Results: Among 80,837 medicine users in the Lifelines, about 1–2 per hundred
participants were exposed to a CYP2D6/2C19/2C9-mediated potential DDI. Overall,
the overlapping time window of three months produced the highest mean kappa values
between the databases i.e. 0.545 (95% CI:0.544–0.545), 0.512 (95% CI:0.511–0.512),
and 0.374 (95% CI:0.373–0.375), respectively. CM-CM had a better level of agreementin.org May 2020 | Volume 11 | Article 6241
Bahar et al. Prevalence and Accuracy of Information on CYP2D6/C19/2C9
Frontiers in Pharmacology | www.frontiers(good) than CM-OM (fair to moderate) and OM-OM combination (poor to moderate). The
influence of gender on concordance values was different for different CYPs. Among older
persons, agreement levels were higher than for the younger population.
Conclusions: CYP2D6/2C19/2C9-mediated potential DDIs were frequent and
concordance of data varied by time window, type of combination, sex and age.
Subsequent studies should rather use a combination of self-reported and pharmacy
database information.Keywords: CYP2D6, CYP2C19, CYP2C9, drug-drug-interaction, Lifelines, IADB.nlINTRODUCTION
Drug-drug interactions (DDIs) are an important contributor to
adverse drug reaction leading to hospitalization or mortality
(Doucet et al., 1996; Montane et al., 2018). CYP2D6, CYP2C19,
and CYP2C9 (CYP2D6/2C19/2C9), subtypes of CYP450 drug
metabolizing enzymes, are commonly involved in mediating
partly inappropriate DDIs as these enzymes metabolize a wide
variety of drugs in clinical practice (Flockhart and Oesterheld,
2000; Bahar et al., 2017b). CYP2D6/2C19/2C9 are highly
polymorphic enzymes and the genetic polymorphisms produce
inter-individual variabilities in drug metabolisms ranging from
poor to accelerated metabolic activities (Zanger and Schwab,
2013). Consequently, the clinical impact of CYP2D6/2C19/2C9-
mediated DDIs might be variable from person to person and
depends on his/her genetic profile (Bahar et al., 2017a). The
information on the clinical relevance and management of DDIs
mediated by different CYP2D6/2C19/2C9 genotypes is therefore
needed. In order to provide the information, the first step that
needs to be done is to generate the data about the burden and
type of potential DDIs mediated by these enzymes in the
general population.
Estimation of the prevalence rate of a potential DDI is
commonly performed using self-reporting methods in which
patients are interviewed or filled out a self-administered
questionnaire (Van den Brandt et al., 1991; Classen et al., 2007;
Secoli et al., 2010). However, this kind of assessment is prone to
information bias, because of inaccurate recall, whichmay influence
the validity of results (Rockenbauer et al., 2001; West et al., 2005).
Hence, it is important to validate drug information collected with
self-reporting methods (Haapea et al., 2010; Hafferty et al., 2018).
The Lifelines cohort is a Dutch three-generation population
cohort that provides a wide variety of medical and non-medical
data, genomic information, and data on medication use (Stolk
et al., 2008; Scholtens et al., 2014). The Lifelines cohort, as a
prospective and long-term database, offers possibilities in
pharmaco-epidemiological studies, such as assessing the impact
of gene polymorphism on the magnitude of DDIs in the
population. However, currently not much is known about the
frequency, type and val idi ty of potent ia l DDIs in
the open population.
This study has both a methodological and an epidemiological
aim: we studied the frequency of potentially interactingin.org 2substrates and inhibitors of the CYP2D6/2C19/2C9 and the
concordance level of the information derived by self-reported
drug use and an analysis of data from a drug-use database. For
the latter aim, information as observed in the Lifelines cohort
was compared with data from a prescription database, the
University of Groningen prescription database IADB.nl, across
type of medications, sex, and age (Visser et al., 2013; Sediq et al.,
2018). A prescription database is regarded as an accurate
database and not to be influenced by so-called recall bias
(Monster et al., 2002; Schneeweiss and Avorn, 2005).
Additionally, IADB.nl has been proven a reliable database in
many pharmaco-epidemiological studies (Daud et al., 2017;
Alfian et al., 2018; Bahar et al., 2018b).MATERIALS AND METHODS
The PharmLines Initiative is a university wide project in which
the data of the Lifelines Cohort study have been linked to the
University of Groningen prescription database IADB.nl. The
project was started in 2017 by the Groningen Research
Institute of Pharmacy, Departments of Epidemiology and
Clinical Pharmacy, Department of Pharmacology of the
University Medical Center Groningen and the Lifelines Cohort
Study (https://www.lifelines.nl/researcher/cohort-and-biobank)
(Sediq et al., 2018).
The Lifelines Cohort
The Lifelines cohort covers 167,729 participants from the
Northern part of the Netherlands, aged 6 months until 93
years old, which were recruited from 2006 until 2013 (Stolk
et al., 2008; Scholtens et al., 2014). It is an observational cohort
study intended to facilitate research on the contribution and
interaction between environmental, genetic, and phenotypic
aspects in the development of chronic diseases and healthy
aging (Stolk et al., 2008; Scholtens et al., 2014). The recruited
participants will be followed for at least 30 years and are asked
to complete a questionnaire every 1.5 years. In addition, once
every 5 years, the participants have a comprehensive physical
examination (Stolk et al., 2008; Scholtens et al., 2014).
Baseline questionnaires included questions about general
information, lifestyle and environment, psychosocial aspects,
and health (including medication use) (Stolk et al., 2008;May 2020 | Volume 11 | Article 624
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information were collected in two ways i.e. a) patients filled
out a questionnaire or b) patients carried the medication at the
time of interview (Sediq et al., 2018). The medication data
regarding their current prescription and dose were recorded
and classified using the Anatomical Therapeutic Chemical
(ATC) coding scheme (Stolk et al., 2008; Scholtens et al.,
2014). The Lifelines population is multigenerational and
generally representative of the Dutch population resided in
the Northern part of the Netherlands (Klijs et al., 2015).
University of Groningen IADB.nl Database
The University of Groningen prescription database IADB.nl has
recorded prescriptions from community pharmacies in the
Netherlands since 1994, and is updated annually (Visser et al.,
2013; Sediq et al., 2018). In 2017, it contained prescription data
of approximately 700,000 individuals from around 72
pharmacies that are located in most of the area where the
Lifelines cohort is also resident. The study population was
reported to represent the general population in Netherlands
(Visser et al., 2013; Sediq et al., 2018). In the IADB.nl, each
patient has a unique and anonymous identifier. Each record
contains information about patient’s sex, date of birth, and
information about his/her prescribed medication such as ATC
code, duration, daily dose, amount prescribed, and dispensing
date (Visser et al., 2013; Sediq et al., 2018). The IADB.nl has no
information about over-the-counter (OTC) drugs and
prescriptions from the hospital.
Study Population and Linkage of
Databases
The study population consists of all medicine users (≥18 years)
in the Lifelines cohort. A Trusted Third Party, Statistics
Netherlands (Dutch: Centraal Bureau voor de Statistiek; CBS),
carried out the linkage of the Lifelines and the IADB.nl records at
the patient level based on postal code in combination with sex
and date of birth. The unique identifiers from both databases
were removed, and once the linkage was completed, each patient
was assigned a new unique code that cannot be traced back to
their previous identifier. Using the new identifier, the data from
both databases could be combined. The complete linking process
was described in more detail by Sediq et al. (Sediq et al., 2018).
Exposures
Exposures were defined as substrates and inhibitors of CYP2D6/
2C19/2C9. We defined a potential DDI as each combination of a
substrate and inhibitor listed in the international standard and
local guideline, Flockhart Table for CYP-mediated drug
interactions and the Dutch Commentaren Medicatiebewaking
book, respectively (Borgsteede, 2015; Flockhart, 2018). Based
on the main indication according to the official product
information, the exposures were classified as: 1) chronically
used medication (CM) for example CYP2D6 substrates such as
beta-blockers (metoprolol), and 2) occasionally used medication
(OM) for example CYP2D6 substrates such as opioidsFrontiers in Pharmacology | www.frontiersin.org 3(tramadol). The full list of medications including their
classification can be found in Supplementary Material 1.
Outcomes
Outcome measures were defined as frequency of potential
CYP2D6/2C19/2C9-mediated DDIs as well as the levels of
agreement between the self-reported information from the
Lifelines cohort and the IADB.nl prescription data on these
potential DDIs across type of medications, age, and sex. If one
patient was exposed to different types of CYP2C9/2D6/2C19
mediated DDIs, we calculated them as one participant with
several incidences of potential DDIs. If the potential DDI was
only found in the Lifelines cohort records, it was categorized
as over-reporting (false positive). If the potential DDI was
only found in the IADB.nl, it was categorized as under-
reporting (false negative). We also provided data on
sensitivity, specificity, negative predictive value/NPV, and
positive predictive value/PPV for the top five potential DDIs
detected in the lifelines database. Different overlapping time
windows (i.e. 1 month, 3 months, 6 months, 9 months, and 1
year) between baseline date of self-reporting medication in the
Lifelines cohort and dispensing date of prescription in the
IADB.nl were applied to determine the optimum time window
for assessing the agreement of both databases. Subgroup
analyses by the type of medication (CM vs OM), age, and
sex were performed to observe the potential influence of these
factors on the agreement. Additionally, we also presented
information about the clinical relevance of the potential
DDIs based on the suggested management provided by
Epocrates® i.e. “contraindicated, avoid combination/use
alternative, modify treatment/monitor and caution”. If
Epocrates® had no recommendation for the potential DDI,
we checked whether Drugs.com, another online drug
interactions screening software, provided suggestions for the
potential DDI. Both of them were reported to have a high
sensitivity for detection of potential DDIs (Perkins et al., 2006;
Bossaer and Thomas, 2017).
Statistical Methods
Comparisons of the prevalence of potential CYP2D6/2C19/
2C9-mediated DDIs [mean (SD)] and the frequency of
participants with the potential DDIs [number (%)] across
age groups (18–59 vs >=60 years old) and sex (men vs women)
were performed by using independent sample t-test. A p-value
which is less than 0.05 (< 0.05) is considered to indicate a
statistically significant difference between comparison groups.
Multivariate analysis of the influence of age and sex on the risk
of having the potential DDIs was conducted by using a binary
logistic regression method to obtain the crude and covariate-
adjusted odds ratios as a measure of association. A p-value <
0.05 and 95% confidence interval (CI) not including 1 are
considered as indicators for significant associations. To
determine the agreement values between the databases on
the potential DDIs, we used Cohen’s kappa statistics and 95%
CI. Altman et al. provided some guidelines to define theMay 2020 | Volume 11 | Article 624
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moderate (0.41–0.60), good (0.61–0.80), and very good
(0.81–1.00) (Altman, 1990).RESULTS
Among of 167,729 Lifelines participants, 80,837 adults were
recorded with self-reported medicine use (mean age 46 years
and 68.5% women) in the cohort at entry (Table 1). Among the
subjects, there were 1,125 (1.4%) self-reported medicine users
exposed to 1,199 potential CYP2D6/2C19/2C9-mediated DDIs
(Figure 1). The prevalence of potential CYP2D6/2C19/2C9-
mediated DDIs was 488, 513, and 198 respectively (Table 2).
Older women had a significantly higher risk to be exposed to
CYP2D6 (OR: 2.159, 95% CI: 1.386–3.363) and CYP2C19 (OR:
1.691, 95% CI: 1.184–2.416) mediated DDIs than older men but
the comparable risks were observed among younger group.FIGURE 1 | Selection of the population study. DDI, drug-drug interaction.TABLE 2 | Prevalence and participants with potential DDIs in the Lifelines cohort.
Variables Prevalence of potential DDIs
(n = 1,199)










































































0.060May 2020 | Volume 11 | ASD, Standard Deviation; DDI, drug-drug interaction.TABLE 1 | Characteristics of participants with self-reported medication use at
entry in the Lifelines cohort database and overlap with IADB.nl prescription
database.
Characteristics Number of participants
(n = 80,837)
Age in year, mean ( ± SD) 46.13 ( ± 14.21)
18-59 years old, N (%) 64,807 (80.17%)
>= 60 years old, N (%) 16,030 (19.83%)
Gender, N women (%) 55,352 (68.50%)
Total participants with CYP2D6/2C19/2C9 mediated
DDI, N(%)
1,125 (1.40%)
Total participants overlapped with IADB.nl database,
N (%)
25,387 (31.41%)
• Age in year, mean ( ± SD) 45.54 ( ± 14.62)
• 18-59 years old, N (%) 20,277 (79.90%)
• >= 60 years old, N (%) 5,110 (20.10%)
• Gender, N women (%) 17,416 (68.60%)
• Total participants with CYP2D6/2C19/2C9
mediated DDI, N (%)
366 (1.44%)SD, Standard Deviation; DDI, drug-drug interaction.rticle 624
Bahar et al. Prevalence and Accuracy of Information on CYP2D6/C19/2C9There was also a tendency that women had an increased risk to
be exposed to CYP2C9 mediated DDIs than men (Table 3).
There were 24% and 47% of CYP2D6 and CYP2C19 mediated
co-prescriptions, respectively, which were in the category of
“avoid combination/use alternative”. Additionally, about 65%,
43%, and 93% of CYP2D6/2C19/2C9-mediated combinations
were in the category of “modify treatment/monitor” according to
the knowledgebase (Figure 2).
Information from 45,160 Lifelines participants could be
linked to the IADB.nl database. Among this linked population,
there were 25,387 self-reported medicine users with comparable
age and sex distribution (mean age 45.5 years and 68.6% women)
as observed in the total medicine users in the Lifelines cohort
(Table 1). Metoprolol-paroxetine (83 events), citalopram-Frontiers in Pharmacology | www.frontiersin.org 5omeprazole (173 events), and diclofenac-paroxetine (51 events)
were the most prevalent potential DDIs mediated by CYP2D6/
2C19/2C9, with good, moderate, and fair agreement of
questionnaire and prescription data, respectively. Data on
kappa, sensitivity, specificity, PPV and PPV values of the top
five most frequent potential DDIs in the Lifelines database can be
found in Table 4. Information on self-reported combinations of
chronically used medications such as metoprolol-fluoxetine had
very good agreement, high sensitivity and specificity as well as
high PPV and NPV. Meanwhile, information on self-reported
combinations with occasionally used medication such as
ibuprofen-paroxetine tended to have fair kappa, sensitivity, and
PPV but high specificity and NPV. The complete list of the
potential DDIs in the Lifelines database and their kappa valuesTABLE 3 | Multivariate analysis on the influence of age and sex on risk of having potential CYP2C9/2D6/2C19 mediated DDIs.
Multivariate analysis Sub-group analysis
Variables Crude OR (95% CI) P-Value Adjusted OR (95% CI) P-Value Variable OR (95% CI) P-Value
CYP2D6 (n = 448)
Age 18–59
18–59 Ref. Ref. Men Ref.
>=60 1.148 (0.918–1.436) 0.228 1.119 (0.956–1.503) 0.116 Women 1.119 (0.881–1.422) 0.358
Sex >=60
Men Ref. Ref. Men Ref.
Women 1.289 (1.044–1.592) 0.018 1.319 (1.066–1.632) 0.011 Women 2.159 (1.386–3.363) 0.001
CYP2C19 (n = 490)
Age 18–59
18–59 Ref. Ref. Men Ref.
>=60 1.606 (1.319–1.956) 0.000002 1.640 (1.343–2.002) 0.000001 Women 0.949 (0.754–1.195) 0.659
Sex >=60
Men Ref. Ref. Men Ref.
Women 1.064 (0.877–1.291) 0.528 1.139 (0.936–1.385) 0.194 Women 1.691 (1.184–2.416) 0.004
CYP2C9 (n = 187)
Age 18–59
18–59 Ref. Ref. Men Ref.
>=60 0.803 (0.546–1.181) 0.265 0.841 (0.570–1.241) 0.383 Women 1.316 (0.906–1.910) 0.149
Sex >=60
Men Ref. Ref. Men Ref.
Women 1.372 (0.986–1.910) 0.061 1.345 (0.964–1.878) 0.081 Women 1.466 (0.702–3.063) 0.308May 2020 | Volume 11 | ASD, Standard Deviation; DDI, drug-drug interaction; OR, Odds Ratio; CI, Confidence Interval.FIGURE 2 | Proportion of potential DDIs based on the suggested managements provided by Epocrates® and Drugs.com.rticle 624
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3, respectively.
The application of different time windows resulted in different
agreement levels of the potential DDIs (Figure 3). Overall, the
time window of three months produced the highest mean kappa
values among potential CYP2D6/2C19/2C9-mediated DDIs i.e.
moderate [0.545 (95% CI: 0.544–0.545)], moderate [0.512 (95%
CI: 0.511–0.512)], and fair [0.374 (95% CI: 0.373–0.375)],
respectively. Extension of the time windows to 6, 9, and 12
months decreased the mean kappa values. The time window of 1
month also produced a low kappa value. For the time window of
3 months, subgroup analysis for the type of medication indicated
the potential DDIs in CM-CM had better level of agreements
(good) than CM-OM (fair to moderate) and OM-OM (poor to
moderate). For the CYP2D6 and CYP2C9 mediated DDIs, CM-
OM combination had better kappa values (fair agreement) than
OM-OM combination (poor agreement). Meanwhile, for the
CYP2C19 mediated DDIs, both the CM-OM and OM-OM
combination had comparable agreement level (moderate). The
summary of the results can be found in Supplementary
Material 3.
Subgroup analysis of agreement by sex showed mixed results
(Figure 4). In CYP2D6 mediated potential DDIs, females appeared
to have a better level of agreement than males. The opposite result
was observed in CYP2C19 and CYP2C9 mediated potential DDIs
where males mostly had a better kappa value compared to females.
Stratification by age indicated that people aged 60 years or older had
a generally better kappa value than the younger population in
CYP2D6/2C19/2C9 mediated potential DDIs (Figure 5).DISCUSSION
In this cross-sectional study, CYP2D6/2C19/2C9-mediated
potential DDIs were frequent and concordance of data varied
by time window, type of medication, sex, and age. We found that
one to two per hundred drug users in the Lifelines cohort were
exposed to a potential CYP2D6/2C19/2C9-mediated DDI at a
short moment in life time. Some of these potential DDIs are
regarded as clinically relevant DDIs such as metoprolol and
CYP2D6 inhibitors combinations. The DDIs may lead to
bradycardia, hypotension, and atrioventricular block (Walley
et al., 1993; Konig et al., 1996; Onalan et al., 2008; Bahar et al.,
2018a). Other relevant DDIs were the combination of CYP2C9
inhibitors that consist of selective serotonin inhibitors (SSRIs),
and nonsteroidal anti-inflammatory drugs (NSAIDs). The
combination of SSRIs and NSAIDs was reported to increase
risk of gastrointestinal bleedings (de Abajo et al., 1999; De Jong
et al., 2003). Yet, the interaction between SSRIs and NSAIDs
might be not solely a pharmacokinetic interaction but also
involves a pharmacodynamic interaction (Moore et al., 2015).
Our findings on the burden of DDIs might have potential clinical
as well as economic implications. A DDI is one of the main
contributors of an adverse drug reaction (ADR) which is one of
the leading causes of hospitalisation and it can cost at minimum
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Bahar et al. Prevalence and Accuracy of Information on CYP2D6/C19/2C9Older women tended to have a higher risk to be exposed to
potential CYP2D6/2C19/2C9-mediated DDIs than older men. A
survey study from the United States about the pattern of drug use
among adults in the outpatient setting indicated that elderly
women (≥65 years old) had the highest burden of medication use
in which 23% and 12% of them used at least five and 10 drugs,
respectively (Kaufman et al., 2002). The risk of experiencing DDI
is increased as the number of drugs taken also increased (Åstrand
et al., 2006). Taking five to seven drugs and 10 to 14 drugs
enhanced the risk of potentially relevant DDI by about 20%–30%
and 40%–60%, respectively (Johnell and Klarin, 2007). Other
studies also reported that being women and old are risk factors
associated with DDIs (Grattagliano et al., 2010; Magro
et al., 2012).
Based on this study, a three-month time window appeared to
result in the best agreement level. This is consistent with the
previous study by Sediq et al. about the validation of single drugFrontiers in Pharmacology | www.frontiersin.org 7used in the Lifelines (Sediq et al., 2018). Additionally, Lau et al.
also found similar finding in their work on the validation of
pharmacy records in Amsterdam, Netherlands (Lau et al., 1997).
One of the possible reasons for this finding is that the Dutch
reimbursement system only allows drugs to be prescribed for a
maximum of 3 months period of supply (Lau et al., 1997). A
comparable study to validate self-reported medication using a
national prescription database in the Danish population also
found a fixed 3 month time window was suitable for checking the
agreement between the two sources of information on medicine
use (Nielsen et al., 2008). Considering the time window is an
important aspect, because a long time window may hamper the
analysis of drugs used on as needed basis and a short time
window may impair the analysis of drugs used chronically
(Johnson and Vollmer, 1991; Nielsen et al., 2008).
Sub-analysis by type of medication indicates self-reported
information on the CM-CM combination was more reliable thanFIGURE 3 | The effect of different time windows on the agreement between the Lifelines cohort and the IADB.nl database.May 2020 | Volume 11 | Article 624
Bahar et al. Prevalence and Accuracy of Information on CYP2D6/C19/2C9information on CM-OM and OM-OM combination. It offers the
possibility to use co-prescription data of the CM-CM
combination from the Lifelines cohort in research. This may
because routinely used medication is more easily remembered by
patients than drugs used occasionally. These results are
consistent with previous studies (Nielsen et al., 2008;
Sarangarm et al., 2012; Cohen et al., 2018).
Furthermore, for CYP2D6 and CYP2C9 related co-prescriptions,
the kappa value of the OM-CM combination (fair agreement) wasFrontiers in Pharmacology | www.frontiersin.org 8higher thanOM-OM (poor agreement) except for CYP2C19. For the
latest, the agreement level of CYP2C19 mediated OM-CM seems
comparable with those of the OM-OM combination (moderate
agreement). There are some possible explanations for this finding.
One is the inclusion of proton pump inhibitors (PPIs) in the OM
groups which are the main drugs in this group. PPIs have wide
therapeutic indications and some of these indications need a chronic
use of PPIs such as Zollinger-Ellisone syndrome, Barrett’s esophagus,
and esophagitis (KNMP, 2018b). Another explanation is theFIGURE 4 | The effect of sex on the agreement between the Lifelines cohort and the IADB.nl database.FIGURE 5 | The effect of age on the agreement between the Lifelines cohort and the IADB.nl database.May 2020 | Volume 11 | Article 624
Bahar et al. Prevalence and Accuracy of Information on CYP2D6/C19/2C9inclusion of diazepam in the OM groups. Diazepam may be used
chronically for treating patients with panic disorder and generalized
anxiety disorder (KNMP, 2018a). Consequently, OM groups not
solely consisted of drugs used ‘as needed’ but also may include
chronically used drugs.
We found that the effect of sex on agreement is not consistent.
Previous studies also reported mixed results. Some reports
showed that men had a better recall accuracy than women
(Linet et al., 1989; Haapea et al., 2010). Meanwhile, other
studies indicated that sex had no influence on the agreement
between self-reported medication use and prescription database
(Van den Brandt et al., 1991; West et al., 1995). Therefore, more
research is needed to determine the effect of sex on the recall
accuracy, and concordance between self-reported medication use
and information from a prescription database.
Our study found the agreement between the Lifelines and the
IADB.nl database records is better in the older population (aged 60
years and older) than in younger adults. This result is in contrast to
previous reports which found aging led to a low agreement between
self-reported medication use and information from a drug database
(Van den Brandt et al., 1991; West et al., 1995). A decrease in
cognitive function and polypharmacy may cause poor recall
information by old patients (Van den Brandt et al., 1991).
However, other studies reported that age did not influence the
agreement level (Sjahid et al., 1998; Lamiae et al., 2010). Themethod
used to collect drug information may determine the influence of
aging in recall bias. If the interviewers visit the patient’s house to
ascertain the consumed drugs or if the patients are helped by their
family in completing the questionnaire, the impact of self-reporting
bias in the old participants (≥ 60 years old) can be reduced (Johnson
and Vollmer, 1991; Lau et al., 1997; Richardson et al., 2013). In the
Lifelines cohort, some participants filled out the questionnaire at
home before visiting the premises. Therefore, the participants were
potentially assisted by their relatives or may directly check their
medication while completing the questionnaire. Meanwhile, some
patients brought their medication at the time of interview so
that interviewers could ascertain their medication list in
the questionnaire.
Another possible culprit of conflicting reports is the type of
medication. Most of the drugs related to CYP2D6/219/2C9 are
mainly groups of drugs used by the old population chronically and
were reported to be associated with a good recall such as cardiac
therapy, antidiabetic agents, anti-thrombotic drugs, anticancer
agents, antidepressant, and antipsychotic agents (Van den Brandt
et al., 1991; Haukka et al., 2007; Gupta et al., 2011; Hafferty et al.,
2018; Sediq et al., 2018). For the last two agents, Haukka et al.
reported a good recall because patients brought their medication at
the time of interview (Haukka et al., 2007). Lastly, the other possible
explanation was the differential distribution of the population in
each subgroup of age which may give a wrong impression about the
influence of different age in the agreement (West et al., 1997). In our
study, about 80% of the population is in the 18–59 years old
subgroup. Therefore, a larger pharmaco-epidemiological study
with a sub-group analysis is needed to elucidate the impact of age
in the concordance of self-reported medication use and data from a
prescription database.Frontiers in Pharmacology | www.frontiersin.org 9Some strengths of our study are worth to be mentioned. Firstly,
the linkage process between both databases is reliable since it was
performed by CBS on individual level. Secondly, the population in
our cohort is large and not limited to a certain group of population
with diseases or using specific medications. Some other studies were
conducted by using a limited sample and only in some particular
groups of patients such as in elderly, pregnant women, patients with
specific medical conditions or using certain drugs (West et al., 1995;
Sjahid et al., 1998; Rockenbauer et al., 2001; Richardson et al., 2013).
Thirdly, we included all types of drugs whichmay potentially trigger
CYP2D6/219/2C9-mediated DDIs. However, there are also some
limitations from our study. Firstly, we only checked the agreement
of prescribed medication but not OTC drugs since the IADB.nl
database has no information onOTC drugs. For example, ibuprofen
is also available over the counter which may explain lower kappa
values in potential DDI combinations. Next, we only had drug
information from community pharmacies and, therefore, if the
drugs recorded in the self-reported questionnaire were obtained
from a hospital, it will not be detected in the IADB.nl and will be
categorized as over-reporting information. Further, some potential
DDIs included in our study were recommended tomanage either by
dose adjustments or monitoring of the possible potential side effects
which have been possibly done by the responsible clinicians.
Meanwhile, some other potential DDIs might not produce
important side effects and only need caution on their use.
However, we still kept them in our analysis because the influence
of genetic polymorphisms on CYP2D6/2C19/2C9 may enhance the
magnitude of the clinical impact of those interactions (Bahar et al.,
2017a). Therefore, it would be valuable to research the interaction of
CYP2D6/2C19/2C9 polymorphisms and CYP2D6/2C19/2C9-
mediated DDIs in the next study. Additionally, we did not
include the combination of substrates and inducers since the
prevalence was too low to allow further analysis. Next, we only
limited the focus of our study on the contribution of the three main
phase I drug metabolizing enzymes (CYP2D6/2C19/2C9) since they
cumulatively metabolize about 42% of drugs currently used in the
clinical practice and mounting evidence has shown that clinical
consequences of genetic polymorphisms are different among the
CYP450 subfamily with CYP2D6/2C19/2C9 polymorphisms
reported to have the most important clinically relevant
implications (Zanger et al., 2008; Zanger and Schwab, 2013; Bahar
et al., 2017a). Therefore, we assume that the CYP2D6/2C19/2C9
mediated DDIs will be the most frequent and relevant DDIs which
will be found to be modified by genetic polymorphism in clinical
practice. However, we would like to emphasize that drug
interactions might also be facilitated by phase II drug
metabolizing enzymes and drug transporters which are also
subject to genetic polymorphisms and still are not optimally
investigated (Board et al., 1998; Kerb, 2006). Furthermore, we
only limited the analysis of the potential DDIs to the pairwise
combination of medications since it reflects current guidelines and
practice related to themanagement of DDIs in the Netherlands (van
Roon et al., 2005; Heringa et al., 2016). However, the DDI might
occur not only in the form of bimodal (involving two drugs)
interaction but also in multimodal (involving more than two
drugs) interactions especially in drugs metabolized by multipleMay 2020 | Volume 11 | Article 624
Bahar et al. Prevalence and Accuracy of Information on CYP2D6/C19/2C9metabolic pathways (Grönlund et al., 2011). Multimodal drug
interactions were reported to produce more severe outcomes than
bimodal interaction since all the metabolic pathways of the drugs
are impaired (Niemi et al., 2003; Niemi et al., 2006). Lastly, our
study had no clinical outcomes of the potential DDIs since in the
current study our focus was limited to study the prevalence of the
potential DDIs and the agreement of drug information between
both databases. This study is pivotal in order to design valid follow-
up studies with the aim to determine the clinical impact of the
observed potential DDIs especially for chronically usedmedications.CONCLUSION
In conclusion, CYP2D6/2C19/2C9-mediated potential DDIs were
frequent and the agreement between the Lifelines cohort and the
IADB.nl differed between time windows. The best concordance level
was achieved at a 3-month time window. CM-CM co-prescription
had a better agreement than CM-OM and OM-OM combinations.
Sex had no consistent influence on the discordance between the
databases. Meanwhile, the older population had a better kappa value
than the younger population. For the next drug study, the self-
reporting data should be complemented with the pharmacy data in
order to achieve a better accuracy in capturing the real word
information on medication use.DATA AVAILABILITY STATEMENT
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